-transparent.png){kind=logo}
Recently, cholecystokinin has been reported to be important in regulating the growth of pancreatic cancer. We investigated the effect of loxiglumide (LXG), a cholecystokinin receptor antagonist, on the invasiveness of two human pancreatic cancer cell lines. Cells were treated with LXG for 24 h, and examined in the invasion assay. The expression and activity of MMP-9 in supernatants from cancer cells were analyzed by Western blotting and zymogram. Interestingly, the invasiveness of cancer cells and expression of MMP-9 were decreased by LXG in a dose-dependent manner. LXG may be a useful therapeutic agent against pancreatic cancer.
Related Publications
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
December 1993,
Cancer,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
June 1999,
International journal of oncology,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
January 1990,
Digestion,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
July 1994,
Pancreas,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
August 1998,
European journal of cancer (Oxford, England : 1990),
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
December 1990,
Gastroenterology,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
February 1991,
Regulatory peptides,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
April 1995,
Pancreas,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
July 2001,
Scandinavian journal of gastroenterology,
M Hirata, and
M Itoh, and
A Tsuchida, and
H Ooishi, and
K Hanada, and
G Kajiyama
November 1994,
European journal of pharmacology,
